Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
A Multi-arm, Adaptive, Group-sequential Trial NETwork to Evaluate Drug Efficacy in Patients With Amyotrophic Lateral Sclerosis (ALS)
Sponsor: Alan Davidson Foundation
Listed as NCT06008249, this PHASE3 trial focuses on Amyotrophic Lateral Sclerosis and remains actively recruiting participants. Sponsored by Alan Davidson Foundation, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE3
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alan Davidson Foundation
- Fight MND
- Luzon Foundation
- MNDA
- My name'5 Doddie Foundation
- Research Foundation Flanders
- Stichting ALS Nederland
- Stichting TRICALS Foundation
- Thierry Latran Foundation
- Ulla-Carin Lindquist Foundation
For direct contact, visit the study record on ClinicalTrials.gov .